Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Pain and Headache Reports
Erschienen in: Current Pain and Headache Reports 2/2016

01.02.2016 | Other Pain (N Vadivelu and A Kaye, Section Editors)

Chronic Daily Headache: Mechanisms and Principles of Management

verfasst von: Amy W. Voigt, Harry J. Gould III

Erschienen in: Current Pain and Headache Reports | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Primary headache is a common malady that is often under-recognized and frequently inadequately managed in spite of the fact that it affects up to 95 % of the population in a lifetime. Many forms of headache, including episodic tension and migraine headaches, if properly diagnosed, are reasonably amenable to treatment, but a smaller, though not insignificant, percent of the population suffer daily from a chronic, intractable form of headache that destroys one’s productivity and quality of life. These patients are frequently seen in neurological practices at a point when treatment options are limited and largely ineffective. In the following review, we will discuss mechanisms drawn from recent studies that address the transition from acute to chronic pain that may apply to the transformation from episodic to chronic daily headaches which may offer opportunities for preempting headache transformation.
Literatur
1.
Linet MS, Stewart WF, Celentano DD, Ziegler D, Sprecher M. An epidemiologic study of headache among adolescents and young adults. JAMA. 1989;261:2211–6.CrossRefPubMed
2.
Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646–57.CrossRefPubMed
3.
Silberstein SD, Lipton RB. Chronic daily headache, including transformed migraine, chronic tension-type headache and medication overuse. In: Silberstein SD, Lipton RB, Dalessio DJ, editors. Wolff’s headache and other head pain. 4th ed. New York: Oxford University Press; 2001. p. 247–82.
4.
Lipton RB. Tracing transformation: chronic migration classification, progression, and epidemiology. Neurology. 2009;72:S3–7.CrossRefPubMed
5.
Raskin NH. Approach to the patient with migraine. Hosp Pract. 1996;31:93–104.
6.••
Evans RW. A rational approach to the management of chronic migraine. Headache. 2013;53:168–76. This is an excellent review of current clinical approaches to treating chronic headaches in terms of medications, office procedures, surgical procedures and non-pharmacologic therapies. CrossRefPubMed
7.
Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American headache society evidence assessment of migraine pharmacotherapies. Headache. 2015;55:3–20.CrossRefPubMed
8.
Afridi SK, Shields KG, Bhola R, Goadsby PJ. Greater occipital nerve injection in primary headache syndromes: prolonged effects from a single injection. Pain. 2006;122:126–9.CrossRefPubMed
9.
Naumann M, So Y, Argoff CE, Childers MK, Dykstra DD, Gronseth GS, et al. Therapeutics and technology assessment subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology. 2008;70:1707–14.CrossRefPubMed
10.
Young WB, Marmura M, Ashkenazi A, Evans RW. Expert opinion: greater occipital nerve and other anesthetic injections for primary headache disorders. Headache. 2008;48:1122–5.CrossRefPubMed
11.
Saper JR, Silberstein SD, Lake III AE, Winters ME. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache. 1994;34:497–502.CrossRefPubMed
12.
Krymchantowski AV, Silva MT, Barbosa JS, Alves LA. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache. 2002;42:510–4.CrossRefPubMed
13.
Tarlaci S. Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. Clin Neuropharmacol. 2009;32:254–8.CrossRefPubMed
14.
15.
Mathew NT, Ali S. Valproate in the treatment of persistent chronic daily headache. An open label study. Headache. 1991;31:71–4.CrossRefPubMed
16.
Spira PJ, Beran RG. Australian gabapentin chronic daily headache group. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology. 2003;61:1753–9.CrossRefPubMed
17.
Rapoport AM, Sheftell FD, Tepper SJ, Bigal M. Levetiracetam in the preventive treatment of transformed migraine. Curr Ther Res. 2005;66:212–21.PubMedCentralCrossRefPubMed
18.
Silberstein SD, Loder E, Forde G, Papadopoulos G, Fairclough D, Greenberg S. The impact of migraine on daily activities: effect of topiramate compared with placebo. Curr Med Res Opin. 2006;22:1021–9.CrossRefPubMed
19.
Silberstein SD, Lipton RB, Dodick DW, Topiramate Chronic Migraine Study Group, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47:170–80.CrossRefPubMed
20.
Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. TOPMAT-MIG-201(TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814–23.CrossRefPubMed
21.
Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev. 2004;2:CD003225.PubMed
22.
23.
Nandha R, Singh H. Renin angiotensin system: a novel target for migraine prophylaxis. Indian J Pharm. 2012;44:157–60.CrossRef
24.•
Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Quality standards subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337–45. This report provides a comprehensive analysis of published studies from 1999 to 2009 that looked at class I and II articles that listed level A evidence of efficacy for medications used for the prevention of episodic migraine. Guidelines are provided for the use of medications that ideally decrease the frequency and severity of migraine attack, thereby reducing medication overuse and the potential transition to chronic headaches. PubMedCentralCrossRefPubMed
25.
Saper JR, Lake III AE, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002;42:470–82.CrossRefPubMed
26.
Tepper SJ, Bigal M, Rapoport A, Sheftell F. Alternative therapies: evidence based evaluation in migraine. Headache Care. 2006;3:57–64.CrossRef
27.
Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1346–53.PubMedCentralCrossRefPubMed
28.
Garza I, Schwedt TJ. Diagnosis and management of chronic daily headache. Semin Neurol. 2010;30:154–66.CrossRefPubMed
29.
Bigal ME, Lipton RB. Clinical course in migraine: conceptualizing migraine transformation. Neurology. 2008;71:848–55.CrossRefPubMed
30.
Kandasamy R, Price TJ. The pharmacology of nociceptor priming. In: Shaible H-G, editor. Pain Control, Handbook of Exper Pharmacol. 2015;227:15–37.
31.
Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. Transformed migraine and medication overuse in a tertiary headache centre—clinical characteristics and treatment outcomes. Cephalalgia. 2004;24:483–90.CrossRefPubMed
32.
Johnson JL, Hutchinson MR, Williams DB. Medication-overuse headache and opioid-induced hyperalgesia: a review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment. Cephalalgia. 2012;33:52–64.CrossRefPubMed
33.
Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. Sci World J. 2007;7:98–111.CrossRef
34.
Hutchinson MR, Northcutt AL, Chao LW, Kearney JJ, Zhang Y, Berkelhammer DL, et al. Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia. Brain Behav Immun. 2008;22:1248–56.PubMedCentralCrossRefPubMed
35.
Meng ID, Cao L. From migraine to chronic daily headache: the biological basis of headache transformation. Headache. 2007;47:1251–8.CrossRefPubMed
36.
37.
Watkins LR, Hutchinson MR, Rice KC, Maier SF. The “toll” of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci. 2009;30:581–91.PubMedCentralCrossRefPubMed
38.
Thalakoti S, Patil VV, Damodaram S, Vause CV, Langford LE, Freeman SE, et al. Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache. 2007;47:1008–23.PubMedCentralCrossRefPubMed
39.
40.
Kandel ER. The molecular biology of memory storage: a dialog between genes and synapses. Biosci Rep. 2004;24:475–522.CrossRefPubMed
41.
42.
43.
Price TJ, Inyang KE. Commonalities between pain and memory mechanisms and their meaning for understanding chronic pain. Prog Mol Biol Transl Sci. 2015;131:409–34.PubMedCentralCrossRefPubMed
44.
Ledeboer A, Sloane EM, Milligan ED, Frank MG, Mahony JH, Maier SF, et al. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain. 2005;115:71–83.CrossRefPubMed
45.
Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX, et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun. 2010;24:83–95.PubMedCentralCrossRefPubMed
46.
Ledeboer A, Liu T, Shumilla JA, Mahoney JH, Vijay S, Gross MI, et al. The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol. 2006;2:279–91.CrossRefPubMed
47.
Rolan P, Hutchinson M, Johnson K. Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease. Expert Opin Pharmacother. 2009;10:2897–904.CrossRefPubMed
48.
Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R. MN166-001 investigators. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology. 2010;74:1033–40.CrossRefPubMed
49.
Volfe Z, Dvilansky A, Nathan I. Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients. Int J Clin Pharmacol Res. 1985;5:243–6.PubMed
50.
51.
Baron EP. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it’s been …. Headache. 2015;55:885–916.CrossRefPubMed
52.
Watkins L, Glia MS. A novel drug discovery target for clinical pain. Nat Rev Drug Discov. 2003;2:973–85.CrossRefPubMed
53.
Vanast WJ. New daily persistent headaches: definition of a benign syndrome. Headache. 1986;26:317.
54.
Diaz-Mitoma F, Vanast WJ, Tyrrell DL. Increased frequency of Epstein-Barr virus excretion in patients with new daily persistent headaches. Lancet. 1987;1:411–5.CrossRefPubMed
55.
Hamada T, Ohshima K, Ide Y, Sakato S, Takamori M. A case of new daily persistent headache with elevated antibodies to Epstein-Barr virus. Jpn J Med. 1991;30:161–3.CrossRefPubMed
56.
Santoni JR, Santoni-Williams CJ. Headache and painful lymphadenopathy in extracranial or systemic infection: etiology of new daily persistent headaches. Intern Med. 1993;32:530–2.CrossRefPubMed
57.
Li D, Rozen TD. The clinical characteristics of new daily persistent headache. Cephalalgia. 2002;22:66–9.CrossRefPubMed
58.
Takase Y, Nakano M, Tatsumi C, Matsuyama T. Clinical features, effectiveness of drug-based treatment, and prognosis of new daily persistent headache (NDPH): 30 cases in Japan. Cephalalgia. 2004;24:955–9.CrossRefPubMed
59.
60.
Rozen TD. New daily persistent headache. In: Goadsby PJ, Dodick DW, editors. Chronic daily headache for clinicians. 1st ed. Hamilton, Ontario: BC Decker Inc; 2005. p. 209–15.
61.••
Lipton RB. Risk factors for and management of medication-over use headache. Continuum (Minneap Minn). 2015;21:1118–31. This review compares MOH (a secondary headache disorder) to chronic daily headache, and provides guidelines to help the practitioner manage and reduce the risk of medication-overuse headache and limit the development of chronic daily headache.
62.
Krusz JC, Scott V, Belanger J. Intravenous propofol: unique effectiveness in treating intractable migraine. Headache. 2000;40:224–30.CrossRefPubMed
63.
Krusz JC. Intravenous treatment of chronic daily headaches in the outpatient headache clinic. Curr Pain Headache Rep. 2006;10:47–53.CrossRefPubMed
64.
65.
Obermann M, Katsarava Z. Management of medication-overuse headache. Expert Rev Neurother. 2007;7:1145–55.CrossRefPubMed
66.
Mathew NT, Kurman R, Perez F. Drug induced refractory headache—clinical features and management. Headache. 1990;30:634–8.CrossRefPubMed
67.
Biondi DM. Is migraine a neuropathic pain syndrome? Curr Pain Headache Rep. 2006;10:167–78.CrossRefPubMed
68.
Woolf CJ, Walters ET. Common patterns of plasticity contributing to nociceptive sensitization in mammals and Aplysia. Trends Neurosci. 1991;14:74–8.CrossRefPubMed
69.
Bliss TV, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol. 1973;232:331–56.PubMedCentralCrossRefPubMed
70.
Cooper JR, Bloom FE, Roth RH. The biochemical basis of neuropharmacology. 6th ed. New York: Oxford University Press; 1991. p. 428–46.
71.
Hebb DO. The organization of behavior. NY: Wiley (Interscience); 1949.
72.
Ji RR, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci. 2003;26:696–705.CrossRefPubMed
73.
74.
Woolf CJ. Central sensitization: uncovering the relation between pain and plasticity. Anesthesiology. 2007;106:864–7.CrossRefPubMed
75.
76.
Pavlov IP. Conditional reflexes. London: Oxford University Press; 1927.
77.
Windholz G. The discovery of the principles of reinforcement, extinction, generalization, and differentiation of conditional reflexes in Pavlov’s laboratories. Pavlov J Biol Sci. 1989;24:35–42.PubMed
78.
79.
Khasar SG, Burkham J, Dina OA, Brown AS, Bogen O, Alessandri-Haber N, et al. Stress induces a switch of intracellular signaling in sensory neurons in a model of generalized pain. J Neurosci. 2008;28:5721–30.PubMedCentralCrossRefPubMed
80.
81.
Melemedjian OK, Asiedu MN, Tillu DV, Peebles KA, Yan J, Ertz N, et al. IL-6- and NGF-induced rapid control of protein synthesis and nociceptive plasticity via convergent signaling to the eIF4F complex. J Neurosci. 2010;30:15113–23.PubMedCentralCrossRefPubMed
82.
Melemedjian OK, Asiedu MN, Tillu DV, Sanoja R, Yan J, Lark A, et al. Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. Mol Pain. 2011;7:70.PubMedCentralCrossRefPubMed
83.
Melemedjian OK, Tillu DV, Asiedu MN, Mandell EK, Moy JK, Blute VM, et al. BDNF regulates atypical PKC at spinal synapses to initiate and maintain a centralized chronic pain state. Mol Pain. 2013;9:12.PubMedCentralCrossRefPubMed
84.
Price TJ, Dussor GAMPK. An emerging target for modification of injury-induced pain plasticity. Neurosci Lett. 2013;557(Pt A):9–18.CrossRefPubMed
85.
Russe OQ, Möser CV, Kynast KL, King TS, Stephan H, Geisslinger G, et al. Activation of the AMP-activated protein kinase reduces inflammatory nociception. J Pain. 2013;14:1330–40.CrossRefPubMed
86.
87.
Ferrari LF, Bogen O, Levine JD. Role of nociceptor αCaMKII in transition from acute to chronic pain (hyperalgesic priming) in male and female rats. J Neurosci. 2013;33:11002–11.PubMedCentralCrossRefPubMed
88.
Rivat C, Bollag L, Richebé P. Mechanisms of regional anaesthesia protection against hyperalgesia and pain chronicization. Curr Opin Anaesthesiol. 2013;26:621–5.CrossRefPubMed
89.
Ashkenazi A, Benlifer A, Korenblit J, Silberstein SD. Zonisamide for migraine prophylaxis in refractory patients. Cephalalgia. 2006;26:1199–202.CrossRefPubMed
90.
Spengos K, Theleritis C, Paparrigopoulos T. Memantine and NMDA antagonism for chronic migraine: a potentially novel therapeutic approach? Headache. 2008;48:284–6.CrossRefPubMed
91.
Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine. Headache. 2008;48:1337–42.CrossRefPubMed
92.
Wang ZJ, Wang LX. Phosphorylation: a molecular switch in opioid tolerance. Life Sci. 2006;79:1681–91.CrossRefPubMed
93.
Cavallo JS, Hamilton BN, Farley J. Behavioral and neural bases of extinction learning in Hermissenda. Front Behav Neurosci. 2014;8(277):1–17.
94.
Cavallo JS, Hamilton BN, Farley J. In vitro extinction learning in Hermissenda: involvement of conditioned inhibition molecules. Front Behav Neurosci. 2014;8(354):1–24.
95.
Hüllemann P, Shao YQ, Manthey G, Binder A, Baron R. Central habituation and distraction alter C-fibre-mediated laser-evoked potential amplitudes. Eur J Pain. 2015. doi:10.​1002/​ejp.​735.
96.
Shealy CN. Guided imagery, mindful meditation, and hypnosis for pain management. Pract Pain Manage. 2015;15:29–34.
97.
Trevelyan EG, Turner WA, Robinson N. Acupuncture for the treatment of phantom limb pain in lower limb amputees: study protocol for a randomized controlled feasibility trial. Trials. 2015;16(158):1–8.
Metadaten
Titel
Chronic Daily Headache: Mechanisms and Principles of Management
verfasst von
Amy W. Voigt
Harry J. Gould III
Publikationsdatum
01.02.2016
Verlag
Springer US
Erschienen in
Current Pain and Headache Reports / Ausgabe 2/2016
Print ISSN: 1531-3433
Elektronische ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-016-0542-3

Weitere Artikel der Ausgabe 2/2016

Current Pain and Headache Reports 2/2016 Zur Ausgabe

Childhood and Adolescent Headache (S Evers, Section Editor)

Lifestyle Factors and Migraine in Childhood

Psychological and Behavioral Aspects of Headache and Pain (D Buse, Section Editor)

Behavioral Weight Loss Treatments for Individuals with Migraine and Obesity

Other Pain (N Vadivelu and A Kaye, Section Editors)

New Labor Pain Treatment Options

Psychological and Behavioral Aspects of Headache and Pain (D Buse, Section Editor)

Model and Processes of Acceptance and Commitment Therapy (ACT) for Chronic Pain Including a Closer Look at the Self

Childhood and Adolescent Headache (S Evers, Section Editor)

Chronic Migraine in Children and Adolescents

Secondary Headache (M Robbins, Section Editor)

Headache in Intracranial and Cervical Artery Dissections

Neu im Fachgebiet AINS

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren
Bildnachweise